Finasteride and Dutasteride – updated safety warnings
The MHRA has reviewed evidence for the risk of psychiatric side effects and sexual dysfunction.
Published: 12 May 2026
The Medicines and Healthcare Products Regulatory Agency (MHRA) has reviewed the evidence for finasteride and dutasteride and the risk of suicidal thoughts and behaviours.
The MHRA has recommended further measures to minimise this risk. The product information for finasteride and dutasteride containing medicines is being updated to provide more information on these side effects.
Further information and advice for healthcare professionals can be found on the MHRA website.